Related Experiment Video
Updated: May 30, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Gender-/Sex-Specific Differences in Clinical Trials in Uro-Oncology]
Marie Christine Roesch1, Lea Sophie Lütje1, Nils Gilbert1
1Department of Urology, University Hospital Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
Abstract:
Subgroup analyses in clinical trials sometimes reveal gender-/sex-dependent differences in cancer outcomes. However, drug approvals are rarely restricted to a specific sex or gender, and recommendations regarding dosage are rarely tailored accordingly. Furthermore, discrepancies exist between the gender-/sex-dependent enrollment rates in clinical trials and real-world incidence or mortality rates. This article highlights gender-/sex differences in clinical trials in uro-oncology.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Cancer Survival Analysis
Hazard Ratio
For example, in a clinical trial...
Comparing the Survival Analysis of Two or More Groups
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

